STRO vs SYK · rev $62.0M vs P/E 35, rev $25.12B
Sutro Biopharma (STRO) versus Stryker Corporation (SYK) — a side-by-side from cached financials, not a winner call.
Sutro Biopharma (STRO) is a biotechnology company listed on NASDAQ.
Stryker Corporation (SYK) is a medical devices company listed on NYSE.
Latest reported STRO revenue for 2024-12-31 was $62.0M. Net income was -$227.5M. Revenue was down 59.6% from 2023-12-31 to 2024-12-31. STRO currently screens at market cap $470.8M.
Latest reported SYK revenue for 2025-12-31 was $25.12B. Net income was $3.25B. Revenue was up 290.2% from 2024-12-31 to 2025-12-31. SYK currently screens at market cap $115.45B and trailing P/E 34.9.
STRO currently screens at market cap $470.8M. SYK currently screens at market cap $115.45B and trailing P/E 34.9.
Not investment advice. Open the STRO and SYK stock pages for the full models.
Not investment advice.